Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma

To analyze whether neoadjuvant chemotherapy (NAC) changes the expression rates of invasive ductal carcinoma (IDC) markers: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, and P53. This was a retrospective study of 112 IDC patients who underw...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jian-Heng, Zhang, Xiang, Song, Jun-Long, Ran, Liang, Luo, Rong, Li, Hong-Yuan, Wang, Yong-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336639/
https://www.ncbi.nlm.nih.gov/pubmed/30633152
http://dx.doi.org/10.1097/MD.0000000000013554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336639/
https://www.ncbi.nlm.nih.gov/pubmed/30633152
http://dx.doi.org/10.1097/MD.0000000000013554

Ejemplares similares